New LENSai API by BioStrand Integrates Large Language Models with Health Data for Advanced Drug Development

BioStrand, a subsidiary of ImmunoPrecise Antibodies Ltd. (IPA), has launched its new LENSai API software, designed to integrate large databases and electronic health records with advanced large language models. This release aims to bolster drug discovery and development capabilities within pharmaceutical, healthcare, and technology sectors.

The LENSai API offers a Customizable Application Programming Interface (API) that enables integration with existing systems, facilitating the incorporation of vast datasets and electronic health records into research workflows. This integration is expected to enhance the efficiency and effectiveness of AI-driven drug discovery processes.

See also: AI Drug Discovery: Unleashing the Potential of Big Data and Machine Learning

Dr. Dirk Van Hyfte, leading the software’s launch, highlighted the significant interest from major healthcare, pharmaceutical, and technology companies. He noted that the integration of BioStrand’s software with electronic health records, combined with the customizable API, provides a powerful tool for analyzing large datasets, potentially leading to the development of safer and more effective drugs.

In silico epitope binning, powered by LENSai technology, offers the ability to analyze over 5,000 sequences to provide insights for early triaging.

BioStrand’s new offering supports various commercial models, including partnerships with upfront payments and royalties, and a subscription service that allows companies to integrate the software into their platforms. The company anticipates the release of a full LENSai data management platform in Q1/Q2 2025.

Topics:
Industry Trends